Media coverage about BioXcel Therapeutics (NASDAQ:BTAI) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioXcel Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5469033931514 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s analysis:
- BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management (finance.yahoo.com)
- BioXcel Therapeutics’ (BTAI) Buy Rating Reaffirmed at HC Wainwright (americanbankingnews.com)
- -$0.35 EPS Expected for BioXcel Therapeutics Inc (BTAI) This Quarter (americanbankingnews.com)
- BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer (finance.yahoo.com)
A number of research analysts recently commented on BTAI shares. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of BioXcel Therapeutics in a research report on Tuesday. Canaccord Genuity started coverage on shares of BioXcel Therapeutics in a research report on Monday, April 2nd. They issued a “buy” rating and a $21.00 target price on the stock. UBS Group started coverage on shares of BioXcel Therapeutics in a research report on Monday, April 2nd. They issued a “buy” rating and a $18.00 target price on the stock. Barclays started coverage on shares of BioXcel Therapeutics in a research report on Monday, April 2nd. They issued an “overweight” rating and a $15.00 target price on the stock. Finally, BMO Capital Markets started coverage on shares of BioXcel Therapeutics in a research report on Monday, April 2nd. They issued an “outperform” rating and a $23.00 target price on the stock. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $20.40.
BioXcel Therapeutics (NASDAQ:BTAI) last posted its earnings results on Monday, May 14th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.11). research analysts forecast that BioXcel Therapeutics will post -1.37 EPS for the current fiscal year.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.